453 related articles for article (PubMed ID: 17562499)
1. Rationale for hypertonic saline therapy for cystic fibrosis lung disease.
Tarran R; Donaldson S; Boucher RC
Semin Respir Crit Care Med; 2007 Jun; 28(3):295-302. PubMed ID: 17562499
[TBL] [Abstract][Full Text] [Related]
2. Evidence for airway surface dehydration as the initiating event in CF airway disease.
Boucher RC
J Intern Med; 2007 Jan; 261(1):5-16. PubMed ID: 17222164
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
Boucher RC
Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805
[TBL] [Abstract][Full Text] [Related]
4. The epithelium as a target for therapy in cystic fibrosis.
Thelin WR; Boucher RC
Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
[TBL] [Abstract][Full Text] [Related]
5. Inhaled hypertonic saline as a therapy for cystic fibrosis.
Elkins MR; Bye PT
Curr Opin Pulm Med; 2006 Nov; 12(6):445-52. PubMed ID: 17053496
[TBL] [Abstract][Full Text] [Related]
6. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.
Mall M; Grubb BR; Harkema JR; O'Neal WK; Boucher RC
Nat Med; 2004 May; 10(5):487-93. PubMed ID: 15077107
[TBL] [Abstract][Full Text] [Related]
7. [Early bronchial inflammation in cystic fibrosis].
Puchelle E
J Soc Biol; 2002; 196(1):29-35. PubMed ID: 12134630
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.
Eng PA; Morton J; Douglass JA; Riedler J; Wilson J; Robertson CF
Pediatr Pulmonol; 1996 Feb; 21(2):77-83. PubMed ID: 8882210
[TBL] [Abstract][Full Text] [Related]
9. [Physiopathology of cystic fibrosis lung disease].
Chinet T
Rev Mal Respir; 1999 Jun; 16(3):339-45. PubMed ID: 10472642
[TBL] [Abstract][Full Text] [Related]
10. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
Mall MA
Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118
[TBL] [Abstract][Full Text] [Related]
11. Cationic lipid:pDNA complexes for the treatment of cystic fibrosis.
Eastman SJ; Scheule RK
Curr Opin Mol Ther; 1999 Apr; 1(2):186-96. PubMed ID: 11715942
[TBL] [Abstract][Full Text] [Related]
12. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy.
Boucher RC
Annu Rev Med; 2007; 58():157-70. PubMed ID: 17217330
[TBL] [Abstract][Full Text] [Related]
13. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function.
Amin R; Subbarao P; Jabar A; Balkovec S; Jensen R; Kerrigan S; Gustafsson P; Ratjen F
Thorax; 2010 May; 65(5):379-83. PubMed ID: 20435858
[TBL] [Abstract][Full Text] [Related]
14. The role of airway epithelium and blood neutrophils in the inflammatory response in cystic fibrosis.
Terheggen-Lagro SW; Rijkers GT; van der Ent CK
J Cyst Fibros; 2005 Aug; 4 Suppl 2():15-23. PubMed ID: 15967736
[TBL] [Abstract][Full Text] [Related]
15. Mucus clearance and lung function in cystic fibrosis with hypertonic saline.
Donaldson SH; Bennett WD; Zeman KL; Knowles MR; Tarran R; Boucher RC
N Engl J Med; 2006 Jan; 354(3):241-50. PubMed ID: 16421365
[TBL] [Abstract][Full Text] [Related]
16. Sendai virus-mediated CFTR gene transfer to the airway epithelium.
Ferrari S; Griesenbach U; Iida A; Farley R; Wright AM; Zhu J; Munkonge FM; Smith SN; You J; Ban H; Inoue M; Chan M; Singh C; Verdon B; Argent BE; Wainwright B; Jeffery PK; Geddes DM; Porteous DJ; Hyde SC; Gray MA; Hasegawa M; Alton EW
Gene Ther; 2007 Oct; 14(19):1371-9. PubMed ID: 17597790
[TBL] [Abstract][Full Text] [Related]
17. [Genetics and cellular biology of cystic fibrosis].
Chinet T; Blouquit S
Rev Prat; 2003 Jan; 53(2):130-4. PubMed ID: 12664842
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis.
Subbarao P; Balkovec S; Solomon M; Ratjen F
Pediatr Pulmonol; 2007 May; 42(5):471-6. PubMed ID: 17436328
[TBL] [Abstract][Full Text] [Related]
19. Introduction to section I: overview of approaches to study cystic fibrosis pathophysiology.
Clunes MT; Boucher RC
Methods Mol Biol; 2011; 742():3-14. PubMed ID: 21547723
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease.
Hirsh AJ; Zhang J; Zamurs A; Fleegle J; Thelin WR; Caldwell RA; Sabater JR; Abraham WM; Donowitz M; Cha B; Johnson KB; St George JA; Johnson MR; Boucher RC
J Pharmacol Exp Ther; 2008 Apr; 325(1):77-88. PubMed ID: 18218832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
